ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

A Phase 2 Study of ZK219477 (ZK-EPO) in Patients With Breast Cancer and Brain Metastases

The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer. ZK219477 is a chemotherapy drug that is thought to work by interfering with the ability of cancer cells to grow and divide. It is a part of a group of drugs called "epothilones" which appear to cause shrinkage of cancer in some patients with breast cancer. It is generally difficult for chemotherapy to enter the brain. However, it is believed that ZK219477 crosses into the brain. We are also studying whether an investigational MRI scan procedure may eventually help to predict which patients will benefit from ZK219477.

Study Overview

• Status: Terminated
• Conditions: Breast Cancer; CNS Disease
• Intervention / Treatment: Drug: ZK219477

Detailed Description

• Participants will be given ZK219477 intravenously over approximately 30 minutes every three weeks.
• During all treatment cycles a physical exam and questions about the participants general health and specific questions about any problems they may be having will be performed.
• At least every three weeks blood tests will be done to assess the effect of ZK219477 on the body.
• After every 2 cycles of treatment, participants will have additional scans to assess the effect of ZK219477 on their cancer. This will include a CT scan of the abdomen, chest, and pelvis, and an MRI of the brain.
• At the time of the standard MRI, participants will be asked to undergo an additional MRI sequence, which means they will be in the MRI machine for approximately 15-20 more minutes.

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Dana-Farber Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Patients must have histologically or cytologically invasive breast cancer, with metastatic disease at the time of screening
• Measurable Central Nervous System (CNS) disease, as defined as at least one lesion > or equal too 10mm in longest dimension
• New or progressive CNS lesions after at least one prior standard CNS-directed therapy for treatment of brain metastases, which could include surgical resection, whole brain radiotherapy (WBRT), and/or stereotactic radiosurgery (SRS). Patients must have received prior WBRT, SRS or both.
• Patient has been evaluated by a radiation oncologist, who feels that the plan to evaluate systemic chemotherapy in place of additional brain radiotherapy is an acceptable option
• No increase in corticosteroid use in the week prior to study entry
• Any number prior lines of chemotherapy for metastatic breast cancer
• 18 years of age of older
• Life expectancy of greater than 12 weeks
• ECOG Performance Status 0-2
• Patients must have normal organ function as outlined in the protocol

Exclusion Criteria:

• Patients who have had chemotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier
• Patients who have had XRT within 3 weeks prior to entering the study or those who have not recovered from adverse events due to XRT
• Patients may not be receiving any other investigational agent
• Patients may not be receiving any cancer-directed therapy
• Prior treatment with investigational chemotherapy for brain metastases
• Prior treatment with epothilone for metastatic breast cancer
• Leptomeningeal carcinomatosis as the only site of CNS involvement.
• Concurrent treatment with an enzyme inducing antiepileptic drug, including phenytoin, carbamezepine, phenobarbital, or oxacarbazepine
• More than 2 seizures over the last four weeks prior to study entry
• Known contraindication to MRI or gadolinium contrast, such as cardiac pacemaker, ocular foreign body, or shrapnel
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant or breastfeeding women.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ZK219477	Drug: ZK219477; Given intravenously over approximately 30 minutes once every 3 weeks; Other Names: ZK-EPO; ZK-Epothilone; Sagopilone

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate in the Central Nervous System (CNS)	Objective response rate is defined as at least a 50 percent reduction in the Central Nervous system target lesion volume compared to the lesion volume at baseline.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Subjects With Adverse Events (Any Grade)	Adverse events per NCI CTCAE	2 years
Objective Response Rate in Non-Central Nervous System (CNS) Sites	Non-CNS response rate (according to RECIST 1.0) limited to patients with measurable non-CNS disease	2 years
Time to Progression at Any Site.	Time from date of registration until the date of the first documentation of progression or date of death (from any cause),whichever came first, up to 2 years from registration. Progression is defined as either progression in the Central Nervous system (CNS) according to volumetric measurement (Freedman et al. 2011) and /or progression in non-Central Nervous System lesion Measured by RECIST 1.0	2 years
Clinical Benefit Rate.	CBR = CR + PR + SD > 24 weeks in CNS with at least stable non-CNS disease	2 years

Collaborators and Investigators

• Sponsor: Nancy Lin, MD
• Collaborators: Bayer; Brigham and Women's Hospital; Breast Cancer Research Foundation

Study record dates

Study Major Dates

• Study Start: July 1, 2007
• Primary Completion (Actual): October 1, 2009
• Study Completion (Actual): January 1, 2012

Study Registration Dates

• First Submitted: July 3, 2007
• First Submitted That Met QC Criteria: July 3, 2007
• First Posted (Estimate): July 4, 2007

Study Record Updates

• Last Update Posted (Estimate): March 14, 2013
• Last Update Submitted That Met QC Criteria: March 12, 2013
• Last Verified: March 1, 2013

More Information

Terms related to this study

• Keywords: brain metastases; metastatic breast cancer; invasive breast cancer; ZK-EPO
• Additional Relevant MeSH Terms: Pathologic Processes; Brain Diseases; Nervous System Diseases; Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Neoplastic Processes; Central Nervous System Neoplasms; Nervous System Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Brain Neoplasms; Central Nervous System Diseases; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Epothilones; Sagopilone
• Other Study ID Numbers: 06-268

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No